Skip to content
Granza Bio logo

Granza Bio

Granza Bio is a YC Winter 2024 (W24) company. Based in San Francisco, CA, USA. Team of 7.

  • Synthetic Biology
  • Biotech
  • Healthcare
  • Therapeutics
  • Oncology

About Granza Bio

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Granza Bio develops cancer and immune-disease therapeutics built on a cytotoxic mechanism called supramolecular attack particles, autonomous killing entities released by cytotoxic immune cells. The biology, discovered in co-founder Prof. Dustin's Oxford lab and published in Science in 2020, enables a new class of targeted medicines that harness the immune system's own killing machinery. The work it replaces is conventional immune-cell therapy approaches that lack this persistent, target-directed killing capability.

From the Y Combinator listing

How Granza Bio describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Reprogramming Immunity for Target-Specific Medicines

Granza Bio is building on the discovery of a previously unknown cytotoxic mechanism in T cells: supramolecular attack particles (SMAPs, Science 2020). This biology reveals a new modality through which cytotoxic lymphocytes deliver persistent, high-intensity killing.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
San Francisco, CA, USA
Team size
7
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works